InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Shares Positive Interim Results on IGC-AD1 for Agitation in Alzheimer’s
IGC Pharma (NYSE American: IGC), a company focused on developing innovative solutions to address Alzheimer’s disease, has announced that interim data from its phase 2 trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer’s at week two compared to placebo. IGC-AD1 targets neuroinflammation and CB1 receptor dysfunction, and the investigational drug contains THC, a principal psychoactive cannabinoid found in cannabis, as…